Medscape Oncology

Dr Mark Kris recognizes the achievements of the dedicated group of researchers who developed antiemetics, helping to overcome one of the most feared side effects of cancer treatment.

Indiana's new 'right to try' law, which allows terminally ill patients access to experimental drugs for compassionate use, offers nothing, but potential harm, says Dr Kathy Miller.

Dr David Kerr reports on a compelling epidemiologic study of lifetime risk for cancer in the United Kingdom demonstrating that for many adults, there is now a 1 in 2 chance of getting cancer.

Dr Gerald Chodak reviews the evidence on adjuvant vs salvage radiation therapy in high-risk men who have undergone radical prostatectomy for prostate cancer.

Dr Bruce Cheson discusses the pros and cons of investigators submitting the same data to multiple meetings.

Dr John Marshall asks clinicians to be mindful of the emotional response cancer patients will have to the PBS Cancer documentary--and to use heightened public awareness to push for research funding.

Dr Gerald Chodak discusses two recent studies that provided support for using active surveillance in certain men with intermediate-risk prostate cancer.

Dr Harold Burstein gets an oncologist's behind-the- cameras view of 'Cancer: The Emperor of All Maladies,' from Barak Goodman, director of the Ken Burns documentary.

Oncologists Cliff Hudis, past president of ASCO, and Sid Mukherjee talk about the PBS documentary adapted from Mukherjee's Pulitzer Prize-winning book, The Emperor of All Maladies.

How does recurrence risk change for a patient who has already survived ovarian cancer for a few years? Maurie Markman comments on a recent Journal of Clinical Oncology paper addressing the question.